Corsens® is a platform technology that measures, displays and reports electromagnetic fluctuations generated by the activity of the heart.
Creavo’s first product to market, Corsens®, will enable healthcare professionals to use the device as an aid to rapidly and accurately rule out patients attending the emergency department with symptoms consistent with those of acute coronary syndrome.
Corsens® an aid to rule out
A majority of patients presenting to emergency departments with chest pain do not get diagnosed with acute coronary syndrome2. However, most will still follow the extensive chest pain pathway – increasing pressure on already strained clinical resources. With Corsens®, healthcare professionals can utilise the MCG results as an aid to rule out active ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome and direct them to the most appropriate care pathway.
This is achieved by detecting distortions in the heart’s magnetic field caused by the presence of ischaemic (lacking oxygen) or necrotic (dead) cells which can be clearly observed in the resulting MCG field map and trace score.
Clear user-friendly interface
Healthcare professionals require quick, accurate information to be presented in a clear and easily-digestible format. Corsens® features a simple touchscreen interface, with a clear graphic data display that can be used by healthcare professionals with very little additional training to that needed to perform a routine ECG.
- Easy to use
Testing is completely passive and requires very little training to perform, allowing healthcare professionals to spend time with their patient, rather than waiting for specialist operators.
- . Rapid Results
The device provides a result within a few minutes which has a high negative predictive value when used in conjunction with a risk assessment protocol to help identify non-cardiac patients early in the triage process.
- . Point of care
The device can be deployed straight to a patient’s bedside at the point of care, without the need for dedicated fixed locations or liquid helium cooling.
Myocardial ischaemia is a condition where blood flow to the heart is reduced. This causes a lack of oxygen which can lead to a ‘heart attack’. Corsens® aids healthcare professionals in ruling out active Ischaemia in patients presenting with symptoms consistent with those of acute coronary syndrome in the emergency department.
Arrhythmia is a disruption of the heart’s normal, regular rhythm. Some arrhythmias, particularly those associated with coronary heart disease, may be life threatening and result in sudden cardiac death (SCD). SCD, both in patients with known risk factors and in people who have had no previous symptoms, is a major public health problem. MCG has the potential to help researchers, and ultimately clinicians, identify those most at risk of SCD, resulting in appropriate, life saving treatments. MCG may also prove useful in helping to identify patients most likely to benefit from expensive treatments for both arrhythmias and severe heart failure.
How much time and money do you anticipate Corsens®could save hospitals?
Based on published literature, it is estimated that up to 70% of patients who present at the emergency department with chest pain have a non-cardiac condition3, but many of these will still go through the complete cardiac triage process which can take many hours. Therefore, identifying a non-cardiac patient early can save a hospital hundreds of pounds per patient. In addition, for inpatients who have had or are having a heart-related problem, it has been proven in various studies that the longer a patient waits for treatment following the onset of chest pain the worse their eventual outcome will be. The device could save a healthcare systems millions of pounds per year.